Tag Archives: Neulasta

June, 2018

  • 5 June

    FDA Approves Mylan and Biocon’s Fulphila, the First Biosimilar to Neulasta

    HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, June 4, 2018/PRNewswire/ — Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug Administration (FDA) has approved Mylan’s Fulphila™ (pegfilgrastim-jmbd), a biosimilar to Neulasta® (pegfilgrastim), co-developed with Biocon. Fulphila has been approved to reduce the duration of febrile neutropenia (fever …

December, 2017

June, 2017

May, 2017

February, 2017

November, 2015